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Abstract
Rationale: In vitro fertilization (IVF) is a common treatment for infertility. In mice, 
IVF is associated with development of glucose intolerance. However, human data are 
limited regarding the metabolic, endocrine and inflammatory effects of IVF therapy 
in IVF-conceived pregnancies.
Objective: To explore effects of IVF therapies on metabolic, endocrine and inflam-
matory parameters in IVF-conceived pregnancy.
Methodology: Twelve-week prospective observational study of adult normoglycae-
mic women, BMI 18.5-38 kg/m2 and ≤ 39 years awaiting IVF therapy. Fasting blood 
samples were collected at baseline and 12 weeks, and serum analysed for reproduc-
tive hormones, glucose, lipids, insulin sensitivity, thyroid status, adiponectin inflam-
matory marker and lipopolysaccharide-binding protein (LBP).
Results: Two hundred and seventy-five women were analysed: 158 IVF-conceived 
pregnant women and 117 with failed IVF. Compared with baseline, nonpregnant 
women had significant (P < .001) increases in 12-week glucose (86.04-87.62 mg/dL), 
insulin (8.72-9.37 µIU/mL), HOMA-IR (1.9-2.1), T-Chol (169.5-174.9 mg/dL), TG (71.0-
83.7 mg/dL) and HDL-C (52.0-54.11 mg/dL) levels. At 12 weeks, pregnant women 
also had (P < .001) increases in T-Chol (177.5-199.5 mg/dL), TG (73.5-126.78 mg/
dL) and HDL-C (55.3-65.1 mg/dL), while a significant reduction in glucose (86.15-
82.19 mg/dL), HbA1c (5.3-5.08%) and TSH (1.71-1.36 µIU/mL) levels from baseline. 
Adiponectin and LBP levels remained the same in either group.
Conclusion: In vitro fertilization hormonal therapy impairs glucose and insulin levels; 
these effects are masked in early pregnancy. Changes in lipid profile occur following 
IVF therapies regardless of pregnancy outcome. Neither adiponectin nor LBP is af-
fected by IVF therapies and during early IVF-conceived pregnancy.
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1  | INTRODUC TION
Infertility is a growing health concern and affects 20% of couples of 
reproductive age.1 Accordingly, assisted reproductive technologies 
have emerged as important therapeutic options for the management 
of infertility, primarily in vitro fertilization (IVF).2 Similar in composi-
tion to IVF, long-term usage of oral contraceptive hormones (based 
on oestrogen and progesterone) associates with adverse effects on 
metabolic, endocrine and inflammatory status, changes in gut micro-
flora and gastrointestinal side effects.3 However, IVF therapies con-
stitute much higher doses but shorter exposure duration to these 
hormones and their safety on both maternal and foetal outcomes 
remains incompletely understood.4,5
Pregnancy is characterized by hormonal-driven changes with 
consequences on metabolic, endocrine and inflammatory status 
and possibly on gut microflora. Insulin sensitivity deteriorates 
starting from the second trimester and subsequent hyperinsulin-
emia.6 Metabolic response to oral contraceptive therapies bear 
similarities to those that occur during the second trimester of 
pregnancy.7,8 Furthermore, in mice IVF therapy is associated with 
development of glucose intolerance.9 Reproductive hormonal 
therapies also alter thyroid function with increased serum thyrox-
ine-binding globulin and total serum thyroxine levels; a compara-
ble effect is seen during pregnancy.10,11 Additionally, increase in 
lipid profile occurs normally mid-pregnancy12 and with contracep-
tives use.7
Physiological changes of pregnancy may also induce micro-in-
flammation and synthesis of inflammatory markers13; a similar effect 
was observed in obese women on oral contraceptive therapies.14 
Inflammation (as a stressor) increases permeability of the gut lining15; 
a surrogate marker of gut endotoxemia is lipopolysaccharide-binding 
protein (LBP). LBP binds bacterial compounds, including lipopolysac-
charides (LPS; outer membrane component of gram-negative bacte-
ria of the gut). Similarly, long-term use of oral contraceptives impairs 
gut permeability, with enhanced levels of LBP and LPS signalling and 
associated cytokine-mediated inflammatory diseases.16 Adiponectin 
is another anti-inflammatory and insulin sensitizer marker, which 
gradually declines in pregnancy.17
Given the high doses of IVF hormones combined with gesta-
tional hormones, physiological changes may hence be manifested 
earlier in IVF-conceived pregnancies. The aim of this study was to 
assess metabolic, endocrine and inflammatory effects of IVF hor-
monal therapies within 12 weeks following its administration in the 
two groups: women with successful IVF-conceived pregnancy and 
women with failed IVF.
2  | METHODS
2.1 | Subjects
Women from multicultural population were recruited from three IVF 
clinic branches in the United Arab Emirates (Dubai, Abu Dhabi and Al 
Ain). Convenient sampling method was used to recruit participants 
who were to start IVF therapy and meeting the inclusion criteria. A 
list of women who were to commence IVF treatment was reviewed 
daily. Following exclusion of diabetes mellitus and thyroid dysfunc-
tion, those subjects who consented for recruitment into the study 
were invited to attend for a baseline fasting blood test (for 10 hours) 
on their screening visit (first day of their IVF treatment program). 
Anthropometric data were also obtained (weight, height, BMI), and 
medical history questionnaires completed by the principle investiga-
tor. Ethical approvals were obtained from local health authorities for 
each of the study centres, and the study complied with the code of 
ethics of the Declaration of Helsinki.
2.2 | Inclusion and exclusion criteria
Women aged 18-39 years of age, presenting with any infertility 
concern and BMI 18.5-38 kg/m2, were eligible for inclusion in the 
study. In addition, women were eligible to participate if it was their 
first ever IVF cycle. Exclusion criteria included current or past his-
tory of diabetes mellitus, thyroid dysfunction and any other chronic 
medical condition such as hepatic, respiratory, haematological and 
cardiovascular disease. Other exclusion criteria included use of any 
therapy that may affect glucose homeostasis, thyroid and/or lipid 
profile, such as growth hormones, oral steroids, anti-inflammatory 
and bronchodilator drugs.
2.3 | IVF intervention
In this prospective cohort (observational), participants were fol-
lowed for 12 weeks of their first IVF cycle. Each subject underwent 
IVF therapy as per clinical need, using the ‘antagonist protocol’, 
which relies on administration of agents to prevent premature ovu-
lation (ie, gonadotropin-releasing hormone antagonist) and to en-
sure adequate oocyte growth.18 The study consisted of four stages 
(shown in Figure 1):
2.3.1 | Stage 1: ovarian stimulation and follicle 
growth (1-12 days)
Depending on baseline levels, follicle-stimulating hormone 
(FSH) was administered alone or combined with luteinizing (LH) 
(300 IU/day). While FSH is needed for ovarian follicular growth 
and endometrial development, LH ensures proper oocyte matura-
tion. Follicle growth (size and numbers) was monitored with fre-
quent ultrasound and blood tests for assessment of serum levels 
of reproductive hormones, and appropriate adjustment of IVF 
therapies. On day 6 of stimulation, gonadotropin-releasing hor-
mone antagonist injection was administered (0.25 mg/day) for a 
better control of endogenous FSH and LH concentrations. One 
dose of human chorionic gonadotropin hormone ‘trigger’ (0.5 mg) 
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was given 36 to 40 hours before schedule of egg retrieval to in-
duce final egg maturation. All other medications were discontin-
ued at that point.
2.3.2 | Stage 2: egg retrieval to embryo transfer 
(week 2)
This includes the period from egg retrieval (‘oocyte pick-up’, 
OPU) to embryo transfer (ET) five days post-OPU. Egg retrieval 
is done by transvaginal ultrasound aspiration. During this stage, 
each retrieved egg undergoes fertilization with collected semen, 
under a microscope and using intracytoplasmic sperm injection 
technique (sperm is directly injected into cytoplasm of mature 
egg). Transvaginal ultrasound guidance is used during ET, which 
is associated with a higher percentage of pregnancy per transfer 
compared with transabdominal ultrasound guidance transfers.19 
Post-OPU, progesterone (tablet: 10 mg three times/day and in-
jection: 50 mg/day) and oestrogen therapies (tablet: 2 mg three 
times/day) were initiated.
2.3.3 | Stage 3: first pregnancy test (week 4)
This includes measurement of serum beta-human chorionic gon-
adotropin (β-HCG). Successful IVF therapy is defined as a clinically 
confirmed pregnancy with a positive serum β-HCG test and a gesta-
tional sac is observed on ultrasound, while unsuccessful refers to a 
negative β-HCG test at 4 weeks. Biochemical pregnancy represents 
a pregnancy confirmed by a positive β-HCG but no sac is visible on 
ultrasound, and ectopic pregnancy is the case where the embryo 
abnormally implants outside the uterus.20 With all cases of nega-
tive β-HCG, ectopic or biochemical pregnancies, all reproductive 
therapies were discontinued at this stage. Biochemical and ectopic 
pregnancies were not included in the unsuccessful group data. For 
all successful pregnancies, subjects were required to continue taking 
their reproductive therapies (oestrogen and progesterone) for the 
first trimester (until around week 12 of pregnancy).
2.3.4 | Stage 4: final blood tests (week 12)
This included assessment of the two groups: women with successful 
IVF-conceived pregnancy and women with failed IVF.
2.4 | Sample size
The primary outcome of the study was to assess changes in glucose 
homeostasis in response to IVF therapy and during IVF-conceived 
pregnancy. Significant changes in glucose and insulin levels are 
expected to occur earlier in IVF-conceived pregnancy as an effect 
of IVF hormones. In order to detect a moderate difference (stand-
ardised difference = 0.5), with 80% power, at significance level of 
0.05 and a ratio of 2:1 for pregnant to nonpregnant women, the 
sample size consisted of 96 pregnant and 48 nonpregnant women. 
According to the latest statistics, pregnancy success rate post–egg 
retrieval is about 30% and this declines with age.21 Therefore, 275 
participants were recruited initially to end up with 96 clinically con-
firmed pregnant.
2.5 | Outcome measures
Blood tests were conducted at baseline and 12-weeks and included 
the following: female reproductive hormones (FSH, LH, oestrogen 
(oestradiol E2 form) and progesterone), fasting plasma glucose, 
serum insulin, glycated haemoglobin A1c (HbA1c), lipid profile, thy-
roid-stimulating hormone (TSH), adiponectin and LBP. At 4-weeks 
of IVF hormonal therapy, fasting glucose and insulin levels were also 
measured, as well as oestrogen, progesterone and β-HCG pregnancy 
test.
Female reproductive hormones, insulin and TSH were measured 
with the electrochemiluminescence immunoassay ECLIA, using 
Cobas E immunoassay analyzers from Roche Diagnostics. Fasting 
plasma glucose was measured by enzymatic reference method with 
hexokinase-glucose-6-phosphate dehydrogenase. Homeostatic 
model assessment of insulin resistance (HOMA-IR) was calculated as 
follows: (fasting plasma insulin x fasting plasma glucose)/ 405.22,23 
Total cholesterol (T-Chol), triglycerides (TG), low-density lipopro-
tein cholesterol (LDL-C) and high-density lipoprotein cholesterol 
(HDL-C) were measured by homogenous enzymatic colorimetric 
method, with Roche/Hitachi Cobas C systems (Cobas C 311/501; 
Roche Diagnostics). Enzyme-linked immunosorbent assay was used 
to determine plasma LBP concentration with human LBP ELISA kit. 
Adiponectin was measured using human ADP/Acrp 30 ELISA kits, 
from Elabscience.
F I G U R E  1   Study stages and IVF hormonal intervention. IVF, in 
vitro fertilization
4  |     COUSSA et Al.
2.6 | Statistical analysis
Data analysis was performed with Statistical Package for the Social 
Sciences (SPSS) software version 21.0 for Windows (SPSS). Non-
normal distribution of parameters was identified using Shapiro-Wilk 
test, and results are hence presented as median and interquartile 
range (IQR). Nonparametric Mann-Whitney U test for two independ-
ent samples was used to compare the two groups (pregnant vs non-
pregnant), at baseline and at 12 weeks. Nonparametric Wilcoxon's 
test for two related samples was used to assess changes at baseline 
vs at 12 weeks within each group (pregnant or nonpregnant). A P 
value of ≤0.05 was used for significance level, with 95% confidence 
interval (CI).
3  | RESULTS
3.1 | Recruitment
A total of 702 women were prescreened by telephone, from whom 
673 were eligible for enrolment in the study. Of these, 354 women 
were recruited into the study as they had ET. Post–embryo trans-
fer, biochemical and ectopic pregnancies (n = 10) were excluded 
and participants were divided into two groups: clinical successful 
pregnancy based on positive β-HCG (pregnant, n = 191) and un-
successful pregnancy outcome based on negative serum β-HCG 
(nonpregnant, n = 153). In the pregnant group (n = 191), 16 partici-
pants did not complete the study, 17 experienced a miscarriage (8%) 
before 12 weeks and they were hence excluded from the study. In 
total, 275 participants completed the study, of which the two groups 
included successful IVF-conceived pregnancy (n = 158) and unsuc-
cessful IVF pregnancy (n = 117; 36 participants did not complete the 
study). Successful pregnancy accounted for 105 single (66%) and 53 
multiple pregnancies (34%). An overview of the recruitment flow is 
shown in Figure 2. The reasons for undergoing IVF therapy were as 
follows: 30% female infertility, 30% male infertility, 15% for gender 
selection and 25% related to other causes (genetic disorders, com-
bination of both male and female infertility and unknown infertility). 
Overall, 45% of women undergoing IVF had a confirmed diagnosis of 
polycystic ovary syndrome (PCOS) (n = 122; 50 nonpregnant and 72 
pregnant), but this was not necessarily the main reason for undergo-
ing IVF in these cases. For the pregnant group overall at baseline, 
22% of women had a BMI ≥ 30 kg/m2 (n = 22), 16% had HbA1c in 
the prediabetic range between 5.7-6.1% (n = 26), and 14% had a past 
history of GDM (n = 22).
At baseline, there was no difference in anthropometrics, endo-
crine and metabolic parameters between pregnant and nonpregnant 
women (data shown in Table 1). Participants overall had a median 
age of 32 (6) years, BMI of 25.4 (6.9) kg/m2, HbA1c of 5.2 (0.52) % 
and TSH of 1.82 (1.4) µIU/mL. At baseline, 21% had a BMI ≥ 30 kg/
m2. Ethnicity of participants was multicultural: 53% Gulf nationals, 
20% from Far East (South and East Asia), 15% Middle Eastern, 8% 
F I G U R E  2   Flow chart of participants’ 
recruitment and enrolment in the study
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Europeans and 4% with African origins. There was a significant in-
crement in weight at 12 weeks in both groups: pregnant women 
BMI: 24.8-25.7 kg/m2, P < .001; nonpregnant women BMI: 25.6-
25.8 kg/m2, P = .002.
3.2 | Glucose and insulin homeostasis
Compared with baseline, glucose level was significantly lower 
at 4 weeks (Δ: −1.68 mg/dL, P = .007) and more so at 12 weeks 
(Δ: −3.96 mg/dL, P = .001) in the pregnant group. At week 12, 
pregnant women had also significant reduction in HbA1c (5.3 to 
5.08%, P < .001). There were no changes in fasting insulin and 
HOMA-IR measures at 4 and 12 weeks of pregnancy compared 
with baseline levels. In contrast, nonpregnant 4-week glucose 
level did not change compared with baseline, while insulin (Δ: 3.1 
µIU/mL, P < .001) and HOMA-IR measures (Δ: 0.7, P = .01) were 
increased. At 12 weeks, nonpregnant women showed statistically 
significant increase in glucose (Δ: 1.56 mg/dL), while insulin (Δ: 
−1.17 µIU/mL) and HOMA-IR (Δ: −0.2) were slightly reduced at 
week 4 but remained higher compared to baseline levels, with 
P < .001 (Table 1 and Figure 3). Regardless of pregnancy status, 
significant changes in glucose and insulin homeostasis occur at 
4 weeks of IVF therapy and dependent on IVF outcome. In relation 
TA B L E  1   Comparison of anthropometrics, metabolic and endocrine parameters at baseline and 12 wk of IVF treatment for pregnant and 
nonpregnant women
Variables
Baseline
P value
4 wk
P value
12 wk
P value
Pregnant 
(n = 158)
Nonpregnant 
(n = 117)
Pregnant 
(n = 158)
Nonpregnant 
(n = 117)
Pregnant 
(n = 158)
Nonpregnant 
(n = 117)
Age (y) 32.0 (7.0) 32.5 (7.00) .32
Weight (kg) 65.5 (18.95) 64.0 (13.97) .58 66.9 (15.9) 64.7 (15.05) .21
Body mass index 
(kg/m2)
24.8 (7.30) 25.55 (6.15) .62 25.7 (6.90) 25.75 (5.73) .86
Female hormones
FSH (IU/L) 6.46 (2.51) 6.65 (2.47) .25
LH (IU/L) 5.99 (3.16) 5.75 (2.70) .39
Ratio FSH/LH 1.10 (0.60) 1.10 (0.50) .14
Oestrogen 
(pg/mL)
41.9 (24.2) 41.04 (19.15) .41 412.15 (857.10) 220.5 (197.90) <.001
Progesterone 
(ng/mL)
0.23 (0.23) 0.24 (0.20) .84 41.07 (37.61) 20.96 (23.95) <.001
Metabolic and endocrine
Fasting 
glucose 
(mg/dL)
86.15 (8.0) 86.04 (10.0) .73 84.47 (7.61) 86.09 (6.55) .01 82.19 (7.19) 87.62 (8.34) <.001
Fasting insulin 
(µIU/mL)
8.84 (6.81) 8.72 (6.41) .93 9.95 (9.28) 11.82 (6.29) .01 9.45 (6.95) 9.37 (5.4) .86
HbA1c (%) 5.3 (0.58) 5.20 (0.50) .77 5.08 (0.53) 5.19 (0.47) .003
HOMA-IR 1.95 (1.52) 1.90 (1.50) .99 2.00 (2.00) 2.60 (1.45) .01 2.00 (1.60) 2.10 (1.5) .17
T-Chol 
(mg/dL)
177.5 (44.95) 169.5 (39.33) .15 199.5 (44.35) 174.9 (48.03) <.001
TG (mg/dL) 73.5 (44.0) 71.0 (41.98) .94 126.78 (60.3) 83.7 (35.15) <.001
LDL-C (mg/dL) 103.0 (38.95) 101.3 (44.0) .61 103.2 (32.43) 102.57 (38.83) .47
HDL-C 
(mg/dL)
55.3 (15.94) 52.0 (18.82) .12 65.1 (18.3) 54.11 (14.30) <.001
TSH (μIU/mL) 1.71 (1.29) 1.95 (1.46) .34 1.36 (1.10) 1.80 (1.05) <.001
ŦAdiponectin 
(μg/mL)
8.87 (1.86) 8.47 (2.17) .17 8.66 (2.41) 8.46 (1.94) .82
ŦLBP (μg/mL) 62.96 (78.83) 55.60 (70.70) .97 45.18 (71.82) 41.29 (88.16) .65
Note: Data presented in median and interquartile range (IQR; IQR = Q3-Q1); Ŧn = 73 (42 pregnant, 31 nonpregnant); P < .05 vs pregnancy by 
independent test.
Abbreviations: FSH, follicle-stimulating hormone; HbA1c, glycated haemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, 
homeostatic model assessment of insulin resistance; LBP, lipopolysaccharide-binding protein; LDL-C, low-density lipoprotein cholesterol; LH, 
luteinizing hormone; T-Chol, total cholesterol; TG, triglycerides; TSH, thyroid-stimulating hormone.
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to history of PCOS, in the pregnant group, 72 women had a his-
tory of PCOS and 86 were non-PCOS prior to pregnancy. At base-
line, women with PCOS presented higher insulin (11.3 vs 9.5 µIU/
mL) and HOMA-IR (2.5 vs 2.05) levels compared to the non-PCOS 
group, with P < .001. At 12 weeks of pregnancy, there were no 
differences in insulin homeostasis parameters between the two 
groups of pregnant women. In the nonpregnant group, baseline 
and 12-week insulin homeostasis did not differ between PCOS 
and non-PCOS women.
3.3 | Lipids
At 12 weeks of pregnancy, lipid profile increased significantly, includ-
ing T-Chol (177.5-199.5 mg/dL), TG (73.5-126.8 mg/dL) and HDL-C 
(55.3-65.1 mg/dL), with P < .001. Similarly, in nonpregnant women, 
T-Chol (169.5-174.9 mg/dL), TG (71.0-83.7 mg/dL) and HDL-C (52.0-
54.1 mg/dL) increased (P < .001).
3.4 | Endocrine and inflammatory outcomes
Pregnant women had significant reductions in TSH (1.7-1.4 µIU/mL; 
P < .001) at 12 weeks, while for nonpregnant group, there was no 
change in TSH level. For all subjects overall, and for each pregnant 
and nonpregnant groups, there were no changes in serum adiponec-
tin or LBP between baseline and 12-weeks.
4  | DISCUSSION
This study showed that IVF hormonal therapy raises levels of glu-
cose, insulin and lipids parameters and reduces insulin sensitivity 
in women with failed IVF (ie, nonpregnant). A similar but more in-
tense effect on impaired insulin sensitivity and glucose intolerance 
was reported with long-term use of oral contraceptives,24,25 sug-
gesting that the duration of the treatment might have more impact 
on glucose and insulin homeostasis than a high dose for a short 
period of time. The effect of IVF hormones on glucose and insulin 
homeostasis was down-regulated by pregnancy, with no change 
observed in insulin level and resistance (HOMA-IR), while glucose 
level was reduced (still within normal range). Glucose level may 
drop early in pregnancy, secondary to a physiological adaptation 
for increased foetoplacental needs, with a focus on carbohydrates 
as a source of energy.6,26 During early gestation, glucose homeo-
stasis remained similar to nonpregnancy level, confirming also 
other studies’ findings conducted in spontaneous pregnancy in 
maintaining euglycaemic levels.27,28 The diabetogenic state from 
hyperinsulinaemia and increased insulin resistance is usually mani-
fested during mid-preganncy27; such changes were not observed 
yet at 12 weeks of IVF-conceived pregnancy. In relation to his-
tory of PCOS, despite higher baseline levels of insulin resistance 
markers (insulin and HOMA-IR; levels still within normal range) in 
PCOS women, 12-week levels were down-regulated to non-PCOS 
pregnant levels.
Unlike the expected effect of oestrogen therapy on raising 
TSH, level remained the same at week 12 for nonpregnant women. 
Two possible explanations may be proposed: (a) IVF medications 
were stopped at 4 weeks and oestrogen therapy has already been 
cleared out from the body; (b) duration of IVF hormone adminis-
tration was too short to induce changes in TSH level. Drop in TSH 
level in the pregnant group is consistent with previous studies 
reporting 20-50% suppression due to the sharp increase in hCG 
concentrations.29,30 Given the potential adverse effect of IVF hor-
mones on impairing glucose and insulin homeostasis and thyroid 
function, more attention should be paid with repeated IVF cycles 
or if IVF hormones were to be provided for a longer period during 
pregnancy.
Female reproductive hormones stimulate synthesis of inflam-
matory markers, which may be associated with change in gut per-
meability13; a similar response was expected with IVF hormonal 
therapy. Interestingly, our data do not support an effect of IVF ther-
apies on serum LBP levels of participants, and by inference change 
F I G U R E  3   Comparison of glucose homeostasis at baseline and 
12 wk of IVF therapy between pregnant and nonpregnant women 
(Graph A. Fasting glucose level; B. Fasting insulin level; C. HOMA-
IR). *P < .05 vs at 12 wk of IVF therapy; ŦP < .05 vs pregnancy; 
HOMA-IR, homeostatic model assessment of insulin resistance; 
IVF, in vitro fertilization
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in gut permeability yet up until 12 weeks. More research is needed 
to elucidate whether LBP can act as a surrogate marker of LPS and 
its related impact on inflammation and gut microflora. Additionally, 
dietary intake is one of the important modulators of intestinal mi-
croflora diversity and richness31; such information was not collected 
in the study. While it is nowadays common to link gut microflora 
impairment with the pathogenesis of certain metabolic disorders 
(such as obesity and T2D), which are also associated with low-grade 
inflammation, it is still however not yet confirmed whether inflam-
mation is the cause or a consequence of the condition.32
Adiponectin is another useful marker of inflammation and has 
glucose-lowering properties.17 Serum adiponectin inversely as-
sociates with BMI, fasting glucose and insulin, and TG levels, and 
positively associates with HDL-C levels.17 These effects cannot be 
ascertained in our study, since interpretations are only based on un-
changed levels of adiponectin within and between groups. In addi-
tion, the type of association between adiponectin and inflammation 
remains controversial in the literature. In contrast to the negative 
typical correlation between adiponectin, obesity and metabolic dis-
ease, a positive association was presented with inflammatory and 
immune-mediated diseases in one study.33
The interplay between inflammation and lipid metabolism is well 
documented, and the two play important role in the pathophysiol-
ogy of metabolic conditions, such as insulin resistance.34 Similarly to 
oral contraceptives, IVF hormones augmented lipid parameters, but 
values remained within normal range possibly due to the short dura-
tion of the treatment.7,25 Metabolic and hormonal changes of preg-
nancy impose changes on lipid homeostasis, which play an important 
role in the provision of energy for the foetus. At 12 weeks of preg-
nancy, lipid profile complied with normal gestational changes with 
increased TG, T-Chol and HDL-C levels.12 The attributable effect of 
IVF hormones on lipids in pregnancy cannot be however determined 
for the following reasons: (a) disparities in duration of IVF hormonal 
administration between the two groups (4 weeks for nonpregnant 
vs until 12 weeks of pregnancy); (b) a cumulative effect would have 
been identified if lipids parameters exceeded the reference ranges 
in pregnancy35; and (c) including a well-matched spontaneous-preg-
nant group would have allowed determination of the magnitude of 
change in lipid profile as an effect of pregnancy alone.
Baseline metabolic and endocrine parameters may differ be-
tween normal vs obese classified BMI, and this may have affected 
our data at 12 weeks. A limitation of this study hence relates to the 
large BMI range of participants. We did not perform subgrouping of 
BMI categories due to lack of power. Dietary intake, urine and stool 
sample collection of participants would have enabled more accurate 
assessment of early changes in gut microflora. Moreover, although 
the euglycaemic clamp protocol is considered as the ‘gold standard’ 
test for assessing changes in insulin sensitivity,36 HOMA-IR is a surro-
gate measure, yet not as precise as the clamp but more practical and 
noninvasive for pregnant women. It is also worth mentioning that 
comparing the effect of IVF hormones to oral contraceptives is ques-
tionable, since the two therapies may differ in their type of bioactive 
oestrogen and progesterone and the duration of the treatment. In 
addition, although IVF therapies constitute much higher doses but 
they present a transient term of exposure to these hormones. In 
addition, pregnancy is a complex condition with significant inherent 
confounding effects on metabolic and inflammatory systems, which 
makes the direct comparison between pregnant and nonpregnant 
groups delicate. Finally, we acknowledge that other potential con-
founding factors may have influenced our data; such factors include 
psychological status and diet of participants. A well-matched spon-
taneous-pregnant group would have allowed the determination of 
magnitude of change in all these parameters as an effect of preg-
nancy alone. Future studies may want to compare more thoroughly 
pregnancies conceived spontaneously vs by IVF.
5  | CONCLUSION
In vitro fertilization therapy induces weight gain and impairment in 
glucose, insulin and lipid homeostasis in failed IVF. Improvement of 
glucose homeostasis, decrease in thyroid profile and increase in lipid 
profile in clinical pregnancy are likely a pregnancy-related effect. 
Neither adiponectin nor LBP is affected by IVF therapies and during 
early IVF-conceived pregnancy. Hence, monitoring of metabolic and 
endocrine parameters in 3 months following IVF should be imple-
mented in clinical practice, particularly with repeated and failed IVF 
attempts.
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